Cretostimogene Phase 3 Trial Shows 68% Risk Reduction in Bladder Cancer
CG Oncology announced top-line results from its Phase 3 PIVOT-006 trial showing a 68% reduction in recurrence risk for non-muscle invasive bladder cancer patients, paving the way for potential regulatory submissions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed